Skip to main content

Unicycive Therapeutics

Rosen Law Files Class Action Against Unicycive Over FDA Disclosure Lapses

Rosen Law Files Class Action Against Unicycive Over FDA Disclosure Lapses

New York – September 12, 2026 -- Rosen Law Firm has filed a securities class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) covering purchasers of the company's securities between December 29, 2025 and June 29, 2026.

Lawsuit alleges Unicycive never audited its manufacturing vendor's facility

The complaint claims Unicycive had not inspected its third-party manufacturing vendor's plant or verified compliance with current good manufacturing practices, leaving the company without a reasonable basis to assert the vendor had fixed deficiencies previously cited by the U.S. Food and Drug Administration.

Unicycive Faces Securities Class Action Over Manufacturing Disclosure Lapses

Unicycive Faces Securities Class Action Over Manufacturing Disclosure Lapses

New York – September 11, 2026 -- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers, alleging violations of federal securities laws tied to the company's handling of a third-party manufacturing vendor's compliance issues.

Lawsuit covers investors who purchased Unicycive stock between December 29, 2025 and June 29, 2026

The complaint alleges Unicycive failed to inspect or audit its third-party manufacturing vendor's facility for compliance with current good manufacturing practices (cGMP). As a result, the company allegedly lacked a reasonable basis to claim the vendor had remedied deficiencies previously cited by the U.S. Food and Drug Administration.